Evaluating sustained adherence to ibrutinib in previously treated chronic lymphocytic leukaemia | Dr Jacqueline Barrientos at Annual Meeting 2015

Evaluating sustained adherence to ibrutinib in previously treated chronic lymphocytic leukaemia | Dr Jacqueline Barrientos at Annual Meeting 2015

User Photo
EMJ

4 years
431 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton's tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukaemia from the phase 3 RESONATE trial. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay